All In Biotech

NDA 009402 · Ph Health

Delestrogen

Estradiol Valerate · Injection

Last checked: Nov 19, 2026Latest source record: Feb 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1954

Jul 15, 1954

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,683

345 Phase 3, 172 recruiting

FAERS reports

778

525 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of “natural” estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogen doses [see WARNINGS , Malignant neoplasms , Endometrial cancer ]. CARDIOVASCULAR AND OTHER RISKS Estrogens and progestins should not be used for the prevention of cardiovascular disease [see WARNINGS , Cardiovascular disorders ]. The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women...

What it is approved for

From the label in effect May 13, 2026.

INDICATIONS AND USAGE DELESTROGEN (estradiol valerate injection, USP) is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only).

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 15, 1954 Original approval
3 products under this application
  • DELESTROGEN · ESTRADIOL VALERATE 40MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INJECTION · Discontinued · TE AO
  • DELESTROGEN · ESTRADIOL VALERATE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AO
  • DELESTROGEN · ESTRADIOL VALERATE 10MG/ML · INJECTABLE, INJECTION · Prescription · TE AO

Clinical trials

Interventional ClinicalTrials.gov studies with "Estradiol Valerate" as an intervention, any sponsor and status, largest first.

All 1,683 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use96
  • headache72
  • drug ineffective71
  • fatigue65
  • nausea59
  • pain53
  • migraine45
  • dyspnoea42
  • weight increased39
  • diarrhoea36
  • abdominal pain30
  • anxiety30

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200414
200510
200610
200721
200817
200913
201022
201118
201239
201311
201427
201520
201628
201728
201862
201928
202047
202155
202252
202358
202465
202577
202656

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Delestrogen (Estradiol Valerate)

2024 spending

$77K

Beneficiaries

209

475 claims

Per beneficiary

$370

$30.53 per unit

View as table
YearSpending
2020$271,566
2021$255,299
2022$170,993
2023$132,341
2024$77,376

Part B: Delestrogen* (Estradiol Valerate*) · HCPCS J1380

2024 spending

$36K

Beneficiaries

524

3,086 claims

Per beneficiary

$69

2024 ASP limit $8.43 per unit

View as table
YearSpending
2020$54,454
2021$61,587
2022$49,945
2023$50,117
2024$36,341

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 307 on PubMed

Sponsor: Ph Health

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.